Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus AVD in early-stage unfavorable classical Hodgkin lymphoma
2016-002626-37Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University of Cologne. Primary endpoints: Complete remission rate at end of treatment and Quality of life. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2016-002626-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002626-37.